552 related articles for article (PubMed ID: 15935874)
1. Molecular basis for improved anthrax vaccines.
Brey RN
Adv Drug Deliv Rev; 2005 Jun; 57(9):1266-92. PubMed ID: 15935874
[TBL] [Abstract][Full Text] [Related]
2. Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.
Lee DY; Chun JH; Ha HJ; Park J; Kim BS; Oh HB; Rhie GE
FEMS Immunol Med Microbiol; 2009 Nov; 57(2):165-72. PubMed ID: 19732139
[TBL] [Abstract][Full Text] [Related]
3. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
4. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
5. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
[TBL] [Abstract][Full Text] [Related]
6. Past, imminent and future human medical countermeasures for anthrax.
Baillie LW
J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809
[TBL] [Abstract][Full Text] [Related]
7. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
[TBL] [Abstract][Full Text] [Related]
8. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170
[TBL] [Abstract][Full Text] [Related]
9. Progress and novel strategies in vaccine development and treatment of anthrax.
Chitlaru T; Altboum Z; Reuveny S; Shafferman A
Immunol Rev; 2011 Jan; 239(1):221-36. PubMed ID: 21198675
[TBL] [Abstract][Full Text] [Related]
10. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
Sloat BR; Cui Z
Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
Sloat BR; Cui Z
J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
[TBL] [Abstract][Full Text] [Related]
13. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.
Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL
Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272
[TBL] [Abstract][Full Text] [Related]
14. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
Gupta M; Alam S; Bhatnagar R
Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
[TBL] [Abstract][Full Text] [Related]
15. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
Sloat BR; Shaker DS; Le UM; Cui Z
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
[TBL] [Abstract][Full Text] [Related]
16. Advances in the development of next-generation anthrax vaccines.
Friedlander AM; Little SF
Vaccine; 2009 Nov; 27 Suppl 4():D28-32. PubMed ID: 19837282
[TBL] [Abstract][Full Text] [Related]
17. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits.
Ribot WJ; Powell BS; Ivins BE; Little SF; Johnson WM; Hoover TA; Norris SL; Adamovicz JJ; Friedlander AM; Andrews GP
Vaccine; 2006 Apr; 24(17):3469-76. PubMed ID: 16519970
[TBL] [Abstract][Full Text] [Related]
18. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.
Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A
Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664
[TBL] [Abstract][Full Text] [Related]
19. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.
Fasanella A; Tonello F; Garofolo G; Muraro L; Carattoli A; Adone R; Montecucco C
Vaccine; 2008 Oct; 26(45):5684-8. PubMed ID: 18775462
[TBL] [Abstract][Full Text] [Related]
20. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.
Livingston BD; Little SF; Luxembourg A; Ellefsen B; Hannaman D
Vaccine; 2010 Jan; 28(4):1056-61. PubMed ID: 19896452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
